Supplementary material to article by C. P. Hernández-Fernández "Effect of Sex in Systemic Psoriasis Therapy: Differences in Prescription, Effectiveness and Safety in the BIOBADADERM Prospective Cohort"

Table SIII. Prescription and effectiveness models of patients treated with modern systemic therapy, measuring the effect of sex (plaque and guttate psoriasis only vs all patients)

Prescription model	Crude OR, (95% CI)	<i>p</i> -value	Adjusted OR, (95% CI)	<i>p</i> -value
Females compared with males (plaque and guttate psoriasis) Females compared with males (All)	1.08 (0.96-1.21) 1.03 (0.93-1.15)	0.2007 0.5710	1.33 (1.14–1.54) 1.33 (1.15–1.55)	<0.0001 0.0001
Effectiveness model	Crude SHR, (95% CI)		Adjusted SHR, (95% CI)	
Ineffectiveness: Females compared with males (plaque and guttate psoriasis) Ineffectiveness: Females compared with males (All)	1.11 (0.94–1.31) 1.14 (0.97–1.33)	0.2084	1.15 (0.97–1.36) 1.17 (1.00–1.38)	0.1120
Remission: Females compared with males (plaque and guttate psoriasis) Remission: Females compared with males (All)	0.97 (0.81–1.16) 0.96 (0.81–1.14)	0.7219 0.6580	1.03 (0.85–1.24) 1.00 (0.83–1.20)	0.7880 0.9640

OR: odds ratio; SHR: subhazard ratio; 95% CI: 95% confidence interval. Shaded areas correspond to variables with a p-value <0.05.